Jiangbo Pharmaceuticals, Inc. ("Jiangbo" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China, today announced that Elsa Sung, the Company's Chief Financial Officer, will be leaving the Company effective March 31, 2011 due to personal reasons that will limit her ability to serve the Company on a full time basis. Ms. Sung has agreed to assist the Company as a consultant on a part-time basis after March 31, 2011 to ensure a smooth transition for her successor. The Company has initiated a search for a new Chief Financial Officer and will make an announcement as soon as a candidate has been chosen.
"We truly appreciate Ms. Sung's many contributions during her tenure and wish her the best as she deals with some unanticipated personal circumstances," said Mr. Linxian Jin, the Company's Chief Executive Officer. "We are actively seeking a qualified successor with a strong background in US GAAP accounting and the global capital markets to lead our finance team as Jiangbo pursues initiatives to accelerate growth and build shareholder value."
No comments:
Post a Comment